TFG Asset Management GP Ltd Makes New Investment in Keros Therapeutics, Inc. (NASDAQ:KROS)

TFG Asset Management GP Ltd purchased a new position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 103,000 shares of the company's stock, valued at approximately $1,630,000. Keros Therapeutics accounts for approximately 0.4% of TFG Asset Management GP Ltd's investment portfolio, making the stock its 18th biggest holding. TFG Asset Management GP Ltd owned approximately 0.25% of Keros Therapeutics at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in KROS. Vanguard Group Inc. lifted its position in Keros Therapeutics by 5.4% during the fourth quarter. Vanguard Group Inc. now owns 1,957,109 shares of the company's stock worth $30,981,000 after buying an additional 100,691 shares during the period. Braidwell LP lifted its holdings in shares of Keros Therapeutics by 167.9% during the 4th quarter. Braidwell LP now owns 1,894,439 shares of the company's stock worth $29,989,000 after acquiring an additional 1,187,199 shares during the period. Darwin Global Management Ltd. lifted its holdings in shares of Keros Therapeutics by 10.7% during the 4th quarter. Darwin Global Management Ltd. now owns 1,687,135 shares of the company's stock worth $26,707,000 after acquiring an additional 163,403 shares during the period. Millennium Management LLC increased its position in Keros Therapeutics by 53.3% during the fourth quarter. Millennium Management LLC now owns 878,159 shares of the company's stock worth $13,901,000 after purchasing an additional 305,169 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in Keros Therapeutics by 5.5% during the fourth quarter. Geode Capital Management LLC now owns 765,436 shares of the company's stock worth $12,120,000 after purchasing an additional 39,815 shares during the period. Hedge funds and other institutional investors own 71.56% of the company's stock.

Keros Therapeutics Stock Performance

Shares of KROS stock traded up $0.12 on Thursday, hitting $14.16. The stock had a trading volume of 411,039 shares, compared to its average volume of 836,562. Keros Therapeutics, Inc. has a 52-week low of $9.12 and a 52-week high of $72.37. The firm has a market capitalization of $575.11 million, a price-to-earnings ratio of -2.72 and a beta of 1.32. The stock's 50 day moving average is $12.58 and its 200-day moving average is $22.18.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported $3.62 earnings per share for the quarter, beating the consensus estimate of ($0.01) by $3.63. The company had revenue of $211.25 million during the quarter, compared to the consensus estimate of $84.62 million. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. During the same period last year, the firm earned ($1.21) earnings per share. Equities analysts expect that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on KROS. Scotiabank cut their target price on Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating on the stock in a research report on Monday, May 12th. Wells Fargo & Company reduced their price objective on Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating on the stock in a research note on Thursday, February 27th. HC Wainwright decreased their target price on Keros Therapeutics from $40.00 to $25.00 and set a "buy" rating for the company in a report on Thursday, May 8th. Truist Financial cut their price target on shares of Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating on the stock in a report on Wednesday, April 9th. Finally, Wedbush reaffirmed a "neutral" rating and set a $15.00 price target on shares of Keros Therapeutics in a research report on Tuesday, April 1st. Six analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, Keros Therapeutics has an average rating of "Moderate Buy" and an average target price of $37.00.

Insider Activity

In other news, major shareholder Adar1 Capital Management, Llc bought 934,258 shares of Keros Therapeutics stock in a transaction on Wednesday, April 9th. The shares were bought at an average price of $10.13 per share, with a total value of $9,464,033.54. Following the acquisition, the insider now directly owns 4,392,737 shares in the company, valued at approximately $44,498,425.81. This represents a 27.01% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 20.60% of the company's stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.